Our mission is to accelerate transformational innovation through the relentless pursuit of groundbreaking science, our entrepreneurial spirit and a collaborative mindset. In 2022, we entered the field of oncology, CAR-T, and antibody therapy research and development with the acquisitions of CellPoint and AboundBio. These transactions have provided us with end-to-end CAR-T development capabilities, with the potential to change the paradigm in the field by implementing a groundbreaking decentralized point-of-care manufacturing model and state-of-the-art fully human antibody-based capabilities for the development of next-generation CAR-Ts and biologics.

Click here to know more!